COMPARATIVE EVALUATION OF P53 IN NORMAL BREAST, FIBROADENOMA, AND CARCINOMA BREAST

KT ATHULYA KRISHNA KUMAR; ABHILASH NP; VANISRI HR

doi:10.22159/ajpcr.2024v17i12.53006

Authors

KT ATHULYA KRISHNA KUMAR Department of Pathology, Chamrajnagar Institute of Medical Sciences, Mysuru, Karnataka, India. https://orcid.org/0009-0002-9378-1776
ABHILASH NP Department of Pathology, Chamrajnagar Institute of Medical Sciences, Mysuru, Karnataka, India.
VANISRI HR Department of Pathology, Chamrajnagar Institute of Medical Sciences, Mysuru, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i12.53006

Keywords:

Fibroadenoma, Carcinoma Breast, P53, Immunohistochemistry

Abstract

Objectives: The objective of this study was to analyze as well as compare the immunohistochemical expression of P53 in normal breast tissue and cases of fibroadenoma and carcinoma breast.

Methods: The present study was a retrospective analysis over a period of 1 year (2022–2023). A total of 60 cases comprising 10 cases of normal breast tissue, 20 cases of fibroadenoma breast, and 30 cases of carcinoma breast were included. Immunohistochemical staining by P53 antigen was performed and slides were graded accordingly as Grade 0, 1, and 2 depending on the staining intensity and percentage.

Results: Correlation of P53 staining across the spectrum of normal breast, fibroadenoma, and carcinoma breast showed a significant association (p=0.01). There was no significant association between the age and level of P53 expression (p=0.1). On evaluating the association between other clinicopathological variables and grade of P53 expression, we found a significant association with regards to tumor size (p=0.0006), tumor grade (p=0.043), lymph-vascular invasion (p=0.019), and nodal metastasis (p=0.025).

Conclusion: P53 may be a possible prognostic marker, to help in better therapeutic management of cases of breast carcinoma.

Downloads

Download data is not yet available.

References

Raj S, Soni S, Aden D, Yadav A, Raj S. Survivin and p53 expression in benign and malignant lesions of breast. IP J Diagn Pathol Oncol. 2022;7(4):229-32. doi: 10.18231/j.jdpo.2022.054

Berg JW, Hutter RV. Breast cancer. Cancer. 1995;75(1):257-69. doi: 10.1002/1097-0142(19950101)75:1+<257:aid-cncr2820751311> 3.0.co;2-y

Guirguis MS, Adrada B, Santiago L, Candelaria R, Arribas E. Mimickers of breast malignancy: Imaging findings, pathologic concordance and clinical management. Insights Imaging. 2021;12(1):53. doi: 10.1186/s13244-021-00991-x, PMID: 33877461

Ajmal M, Khan M, Van Fossen K. Breast fibroadenoma. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535345 [Last accessed on 2024 Jun 12].

Stachs A, Stubert J, Reimer T, Hartmann S. Benign breast disease in women. Dtsch Ärztebl Int. 2019;116(33-34):565-74. doi: 10.3238/arztebl.2019.0565, PMID: 31554551

Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13(9):640-5. doi: 10.1046/ j.1525-1497.1998.cr188.x, PMID: 9754521

Li J, Humphreys K, Ho PJ, Eriksson M, Darai-Ramqvist E, Lindström LS, et al. Family history, reproductive, and lifestyle risk factors for fibroadenoma and breast cancer. JNCI Cancer Spectr. 2018;2(3):pky051. doi: 10.1093/jncics/pky051, PMID: 31360866

Costa RS, Silva IF. P53 Expression in benign breast disease development: A systematic review. Asian Pac J Cancer Prev. 2020;21(9):2485-91. doi: 10.31557/APJCP.2020.21.9.2485, PMID: 32986343

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10. doi: 10.1038/35042675, PMID: 11099028

Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. 1998;273(1):1-4. doi: 10.1074/jbc.273.1.1, PMID: 9417035

Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer. 1999;80(12):1968-73. doi: 10.1038/sj.bjc.6690628, PMID: 10471047

Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996;13(9):1971-81. PMID: 8934544

Gogoi S, Das B, Borgohain M, Gogoi G, Das J. Ki67 and P53 expression in breast cancer and their correlation with clinicopathological parameters. Indian J Pathol Oncol. 2021;8(4):478-84. doi: 10.18231/j. ijpo.2021.099

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-31. doi: 10.1016/s0092-8674(00)81871-1,

PMID: 9039259

Rivoire WA, Corleta HE, Silva IS.Molecular biology of cervical cancer. Rev Bras Cancerol. 2001; 47(2): 179-84. doi: 10.32635/2176-9745. RBC.2001v47n2.2332

Bourdon JC, de Laurenzi V, Melino G, Lane D. p53: 25 years of research and more questions to answer. Cell Death Differ. 2003;10(4):397-9. doi: 10.1038/sj.cdd.4401243, PMID: 12719714

Bourdon JC. p53 and its isoforms in cancer. Br J Cancer. 2007;97(3):277-82. doi: 10.1038/sj.bjc.6603886, PMID: 17637683

Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: The gatekeepers and the caretakers. Am J Clin Pathol. 2005;124:S16-28. doi: 10.1309/5XW3L8LU445QWGQR, PMID: 16468415

Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994;54(11):2914-8. PMID: 8187077

Ekundina OV, Ejelue CC, Apulu OP, Ayodele OO. Cell proliferation, contact inhibition, and apoptosis profiling in a benign and malignant breast lesion. Int J Oncol Res. 2022;5:034. doi: 10.23937/2643- 4563/1710034

Angèle S, Jones C, Reis Filho JS, Fulford LG, Treilleux I, Lakhani SR, et al. Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol. 2004;57(11):1179-84. doi: 10.1136/ jcp.2004.017434, PMID: 15509680

Niezabitowski A, Lackowska B, Rys J, Kruczak A, Kowalska T, Mitus J, et al. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: Immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat. 2001;65(1):77- 85. doi: 10.1023/a:1006457304526, PMID: 11245343

Ioakim-Liossi A, Markopoulos C, Karakitsos P, Safioleas M, Gogas J, Vaiopoulos G. p53 protein expression in benign and malignant breast lesions. Acta Cytol. 1998;42(4):918-22. doi: 10.1159/000331968, PMID: 9684577

Dash SS, Alaka S, Anupa T. P53 expression in breast carcinoma and its association with tumor aggressiveness. J Datta Meghe Inst Med Sci Univ. 2021;16(2):266-72.

Gupta KK, Dash AK, Mishra DP. Correlation of p53 expression with clinicopathological characteristics of breast carcinoma. Ann Pathol Lab Med. 2016;3:A162-70.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 2004;6(1):R24-30. doi: 10.1186/bcr738, PMID: 14680497

Li JP, Zhang XM, Zhang Z, Zheng LH, Jindal S, Liu YJ. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine (Baltimore). 2019;98(18):e15449. doi: 10.1097/MD.0000000000015449, PMID: 31045815

COMPARATIVE EVALUATION OF P53 IN NORMAL BREAST, FIBROADENOMA, AND CARCINOMA BREAST

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section